MedTrace Logo

Validation of the Utility of Rare Disease Intelligence Platform

NCT02748044 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2016-04-22

No results posted yet for this study

Summary

The prevention and treatment of diseases via artificial intelligence represents an ultimate goal in computational medicine. The artificial intelligence for systematic clinical application has not yet been successfully validated. Currently, the main prevention strategy for rare diseases is to build specialized care centers. However, these centers are scattered, and their coverage is insufficient, resulting in inadequate health care among a large proportion of rare disease patients. Here, the investigators use "deep learning" to create CC-Cruiser, an intelligence agent involving three functional networks: "pick-up networks" for diagnostics, "evaluation networks" for risk stratification and "strategist networks" to provide assisted treatment decisions. The investigator also establish a cloud intelligence platform for multi-hospital collaboration and conduct clinical trial and website-based study to validate its versatility.

Conditions

  • Cataract
  • Artificial Intelligence

Interventions

DEVICE

CC-Cruiser

An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts

Sponsors & Collaborators

  • Ministry of Health, China

    collaborator OTHER_GOV

  • Xidian University

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Haotian Lin, M.D., Ph.D · Zhongshan Ophthalmic Center, Sun Yat-sen University

  • Yizhi Liu, M.D., Ph.D · Zhongshan Ophthalmic Center, Sun Yat-sen University

  • Erping Long, M.D., Ph.D · Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02748044 on ClinicalTrials.gov